Coloplast surpasses guidance and sets out to launch share buyback program

Coloplast's Q1 fiscal report shows better overall results than what analysts expected. The firm also announces its plans to launch a share buyback program worth DKK 500m.

Photo: Coloplast / PR

Tuesday morning Danish medtech firm Coloplast presented its Q1 report for the staggered fiscal year 2020/2021, which contained some surprises compared with what analysts had expected.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs